Filing Details

Accession Number:
0000899243-16-013153
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-02-11 19:23:31
Reporting Period:
2016-02-09
Filing Date:
2016-02-11
Accepted Time:
2016-02-11 19:23:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1184156 Thomas Craig One Idexx Drive
Westbrook ME 04092
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-02-09 2,054 $17.19 24,352 No 4 M Direct
Common Stock Disposition 2016-02-09 2,054 $69.52 22,298 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2016-02-09 2,054 $0.00 2,054 $17.19
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-02-13 No 4 M Direct
Footnotes
  1. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $69.2738 to $69.8301 inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
  2. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,527 shares on February 14, 2010, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  3. Not applicable.